4.8 Review

Deep brain stimulation of the medial forebrain bundle: a strategy to modulate the reward system and manage treatment-resistant depression

Journal

MOLECULAR PSYCHIATRY
Volume 27, Issue 1, Pages 574-592

Publisher

SPRINGERNATURE
DOI: 10.1038/s41380-021-01100-6

Keywords

-

Funding

  1. Pat Rutherford Jr. Chair in Psychiatry
  2. John S. Dunn Foundation
  3. Anne and Don Fizer Foundation Endowment for Depression Research

Ask authors/readers for more resources

In this article, the medial forebrain bundle and its importance in the modulation of affective disorders such as major depression is discussed. The role of the reward system in depression, particularly in anhedonia and lack of motivation, is emphasized. Recent trials have shown promising results in using deep brain stimulation (DBS) to alleviate depressive symptoms through modulation of this white matter pathway.
The medial forebrain bundle-a white matter pathway projecting from the ventral tegmental area-is a structure that has been under a lot of scrutinies recently due to its implications in the modulation of certain affective disorders such as major depression. In the following, we will discuss major depression in the context of being a disorder dependent on multiple relevant networks, the pathological performance of which is responsible for the manifestation of various symptoms of the disease which extend into emotional, motivational, physiological, and also cognitive domains of daily living. We will focus on the reward system, an evolutionarily conserved pathway whose underperformance leads to anhedonia and lack of motivation, which are key traits in depression. In the field of deep brain stimulation (DBS), different hypothesis-driven targets have been chosen as the subject of clinical trials on efficacy in the treatment-resistant depressed patient. The medial forebrain bundle is one such target for DBS, and has had remarkably rapid success in alleviating depressive symptoms, improving anhedonia and motivation. We will review what we have learned from pre-clinical animal studies on defining this white matter tract, its connectivity, and the complex molecular (i.e., neurotransmitter) mechanisms by which its modulation exerts its effects. Imaging studies in the form of tractographic depictions have elucidated its presence in the human brain. Such has led to ongoing clinical trials of DBS targeting this pathway to assess efficacy, which is promising yet still lack in sufficient numbers. Ultimately, one must confirm the mechanism of action and validate proof of antidepressant effect in order to have such treatment become mainstream, to promote widespread improvement in the quality of life of suffering patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available